WO2009070234A3 - Complexation of fatty acid-conjugated molecules with albumin - Google Patents

Complexation of fatty acid-conjugated molecules with albumin Download PDF

Info

Publication number
WO2009070234A3
WO2009070234A3 PCT/US2008/012943 US2008012943W WO2009070234A3 WO 2009070234 A3 WO2009070234 A3 WO 2009070234A3 US 2008012943 W US2008012943 W US 2008012943W WO 2009070234 A3 WO2009070234 A3 WO 2009070234A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
complexation
albumin
conjugated molecules
molecules
Prior art date
Application number
PCT/US2008/012943
Other languages
French (fr)
Other versions
WO2009070234A2 (en
Inventor
Zhiyu Li
Russell Digate
Original Assignee
The University Of The Sciences In Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of The Sciences In Philadelphia filed Critical The University Of The Sciences In Philadelphia
Priority to US12/743,371 priority Critical patent/US8598311B2/en
Publication of WO2009070234A2 publication Critical patent/WO2009070234A2/en
Publication of WO2009070234A3 publication Critical patent/WO2009070234A3/en
Priority to US14/095,259 priority patent/US9309303B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The technology described herein is directed to conjugating various therapeutic or functional molecules, such small chemical drugs, peptides, oligonucleotides, isotopes and imaging regents with fatty acids, such as LCFAs. The fatty acid-conjugated molecules are complexed with a human serum albumin protein in vitro.
PCT/US2008/012943 2007-11-21 2008-11-20 Complexation of fatty acid-conjugated molecules with albumin WO2009070234A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/743,371 US8598311B2 (en) 2007-11-21 2008-11-20 Complexation of fatty acid-conjugated molecules with albumin
US14/095,259 US9309303B2 (en) 2007-11-21 2013-12-03 Complexation of fatty acid-conjugated molecules with albumin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US405607P 2007-11-21 2007-11-21
US61/004,056 2007-11-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/743,371 A-371-Of-International US8598311B2 (en) 2007-11-21 2008-11-20 Complexation of fatty acid-conjugated molecules with albumin
US14/095,259 Division US9309303B2 (en) 2007-11-21 2013-12-03 Complexation of fatty acid-conjugated molecules with albumin

Publications (2)

Publication Number Publication Date
WO2009070234A2 WO2009070234A2 (en) 2009-06-04
WO2009070234A3 true WO2009070234A3 (en) 2009-11-12

Family

ID=40679190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012943 WO2009070234A2 (en) 2007-11-21 2008-11-20 Complexation of fatty acid-conjugated molecules with albumin

Country Status (2)

Country Link
US (2) US8598311B2 (en)
WO (1) WO2009070234A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496329A (en) * 2016-11-04 2017-03-15 华中科技大学同济医学院附属协和医院 A kind of fusion protein containing collagen protein binding structural domain

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3168618B1 (en) 2006-04-04 2018-11-21 Singulex, Inc. Highly sensitive methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA2762612A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
JP6300380B2 (en) 2012-12-26 2018-03-28 ナショナル ユニバーシティ オブ シンガポール Amino-triazolyl-body pie compound with large Stokes shift and application to live neuronal staining and probing of human serum albumin FA1 drug site
US10053498B2 (en) 2014-11-21 2018-08-21 University of the Sciences of Philadelphia Compositions comprising serum albumin and p53 peptides fusion proteins
WO2017095201A1 (en) * 2015-12-02 2017-06-08 한미약품 주식회사 Protein complex using fatty acid derivative, and preparation method therefor
WO2021050521A1 (en) * 2019-09-10 2021-03-18 The Broad Institute, Inc. Compositions, methods and uses for free fatty acid screening of cells at scale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879907A (en) * 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580313C (en) * 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
CA2667678A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879907A (en) * 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20050238664A1 (en) * 2000-02-08 2005-10-27 Hunt Terrence J Botulinum toxin pharmaceutical compositions with multiple stabilizers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RONALD T. RAINES ET AL.: "Replacing a surface loop endows ribonuclease A with angiogenic activity.", J BIOL CHEM., vol. 270, no. 29, 21 July 1995 (1995-07-21), pages 17180 - 17184 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496329A (en) * 2016-11-04 2017-03-15 华中科技大学同济医学院附属协和医院 A kind of fusion protein containing collagen protein binding structural domain

Also Published As

Publication number Publication date
WO2009070234A2 (en) 2009-06-04
US20100272644A1 (en) 2010-10-28
US8598311B2 (en) 2013-12-03
US9309303B2 (en) 2016-04-12
US20140286863A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
WO2009070234A3 (en) Complexation of fatty acid-conjugated molecules with albumin
WO2007062610A3 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
ZA201008048B (en) Human serum albumin linkers and conjugates thereof
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
WO2008073162A3 (en) Lysine acetylation sites
WO2006010153A3 (en) Lipid-amino acid conjugates and methods of use
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2008058963A8 (en) Immobilization of membrane proteins onto supports via an amphiphile
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
WO2006132670A3 (en) Auristatins having an aminobenzoic acid unit at the n terminus
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009051220A1 (en) Antibody capable of specifically binding to aβ oligomer, and use thereof
WO2010111018A8 (en) Antibody drug conjugates (adc) that bind to 24p4c12 proteins
AP2957A (en) New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs
WO2007119011A3 (en) N protein fusion proteins of a virus in the paramyxoviridae-protein of interest family
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
EP1976554A4 (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP1972639A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2008028934A8 (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2007095729A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
WO2010054377A3 (en) Fully human antibodies against n-cadherin
IL212215A0 (en) Use of lipid conjugates in the treatment of disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855738

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12743371

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08855738

Country of ref document: EP

Kind code of ref document: A2